GW 501516

GW 501516

CAT N°: 10004272
Price:

From 66.00 56.10

Peroxisome proliferator-activated receptor δ (PPARδ) stimulation or over-expression in adipocytes leads to increased fatty acid oxidation, improved exercise tolerance, and resistance to obesity.{11581} GW 501516 is the first highly selective synthetic PPARδ agonist available. GW 501516 binds to human PPARδ with an IC50 value of 1 nM, and is at least 100-fold selective for PPARδ compared to PPARα and PPARγ.{11580} In obese primates, GW 501516 increases high density lipoprotein cholesterol and apolipoprotein A-1 specific reverse cholesterol transport.{11379} GW 501516 is therefore a model compound for a new type of obesity therapeutic, as well as a selective pharmacological tool for understanding lipid metabolism.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 2-[2-methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]-acetic acid
  • Correlated keywords
    • GW501516 PPARd PPARδ PPAR-d PPAR-δ peroxisome proliferator-activated receptor cholesterol HDL anti-obesity GW1516 antiobesity
  • Product Overview:
    Peroxisome proliferator-activated receptor δ (PPARδ) stimulation or over-expression in adipocytes leads to increased fatty acid oxidation, improved exercise tolerance, and resistance to obesity.{11581} GW 501516 is the first highly selective synthetic PPARδ agonist available. GW 501516 binds to human PPARδ with an IC50 value of 1 nM, and is at least 100-fold selective for PPARδ compared to PPARα and PPARγ.{11580} In obese primates, GW 501516 increases high density lipoprotein cholesterol and apolipoprotein A-1 specific reverse cholesterol transport.{11379} GW 501516 is therefore a model compound for a new type of obesity therapeutic, as well as a selective pharmacological tool for understanding lipid metabolism.

We also advise you